Chapter 93: Management of ST-Elevation Myocardial Infarction

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive.

Today we are setting up like a one -on -one tutoring environment tailored specifically for you, advanced practice nursing and physician assistant students.

Today we are extracting the key clinical insights from chapter 93 of Lenz Pharmacotherapeutics.

We are focusing entirely on the management of ST elevation myocardial infarction or STEMI.

If you think of the human heart like an engine, a STEMI is basically what happens when the main fuel line is completely and suddenly blocked.

You don't just have an engine that's sputtered out, right?

You have an engine that is actively destroying itself the longer it runs dry.

That's a really good way to put it.

And the priority isn't just to somehow restart it.

The priority is to minimize irreversible tissue damage while racing against the clock to clear that blockage.

Right, and our mission for this session is to master the what, the how, and well most importantly the why of STEMI pharmacotherapy.

Because in advanced clinical practice just memorizing a list of drugs will only get you so far.

Exactly.

You have to logically track how the underlying pathophysiology dictates therapeutic goals, right?

Which then drive rational drug selection, exact dosing, and safe patient -centered outcomes.

So let's start by unpacking that underlying pathophysiology because it's really the why behind every single treatment we're going to discuss.

Yeah, definitely.

By definition, a STEMI is myocardial necrosis resulting from local ischemia.

Right, and on a clinical level this is almost always caused by a partial or complete blockage of a coronary artery.

Yeah.

Usually right at the site of a ruptured atherosclerotic plaque.

Yeah.

But what is actually happening on a like microscopic level in those first few seconds?

Well the core injury fundamentally stems from a severe supply and demand imbalance.

Yeah.

I mean the heart muscle demands oxygen to function and the blocked artery simply cannot supply it.

Makes sense.

And when that happens the local metabolic changes are incredibly rapid.

Within seconds of that occlusion the cardiac cells are forced to shift from aerobic to anaerobic metabolism.

Which anaerobic metabolism is horribly inefficient, right?

It produces a fraction of the energy and generates lactic acid as a byproduct.

Oh yeah, completely.

The high energy stores of ATP and creatine phosphate become completely deflated very quickly and without that energy contraction in the affected region just ceases.

The muscle just stops pumping.

Exactly.

But the cellular crisis goes deeper than that.

You get this dangerous redistribution of ions across the cell membranes.

Because of that anaerobic shift.

Right.

Yeah.

Hydrogen ions start accumulating in the myocardium which causes severe local acidosis.

Meanwhile calcium ions which are crucial for muscle contraction and relaxation get sequestered inside the mitochondria.

So you have a muscle that's highly acidic and completely starved of functional calcium.

Yeah.

And that combination alters the distensibility of the cardiac muscle.

It literally changes how the tissue physically yields and stretches.

It does.

And it doesn't stop with calcium and hydrogen unfortunately.

Sodium ions begin to accumulate inside the myocardial cells too which draws in water and promotes severe intracellular edema.

And finally potassium ions are lost from the cells into the extracellular space.

And that potassium dumping ruins the resting membrane potential setting the perfect stage for fatal ventricular dysrhythmias.

That's exactly it.

Wait, let me push back on the test notes that if blood flow isn't restored actual cell death begins within 20 minutes.

But it also says we measure indices of death much later.

So if cell death begins in just 20 minutes how much time do clinicians actually have before the heart structure is permanently compromised?

So that gap between initial cell death and structural failure that is where clinical intervention lives.

While the necrosis starts at that 20 minute mark clear indices of that death like myocyte disruption or coagulative necrosis.

And the elevation of cardiac proteins in the blood right like troponins.

Yes exactly.

Those take time to accumulate.

They are fully present and measurable by 24 hours.

So the damage is done but the physical threat to the heart's architecture is just beginning.

Right.

By day four the infarcted area undergoes a massive monocyte infiltration.

These white blood cells come in to clear out the dead myocytes.

But in the process of eating with dead tissue they drastically weaken the myocardial wall.

So around day four that tissue is incredibly vulnerable to actually rupturing.

Which is obviously a catastrophic event.

And you don't get dense scar formation until what four to six weeks later.

Yeah about four to six weeks.

And all this structural damage triggers what we call ventricular remodeling.

Right.

Which is driven in large part by the local production of angiotensin the second.

Exactly.

The ventricular mass increases and the chambers literally change in volume and shape to compensate for the dead zone.

And this remodeling directly sets the stage for heart failure.

It does.

To put the math of a left ventricular or LV infarction into perspective if you damage 10 percent of the LV mass your ejection fraction is measurably reduced.

Wow just 10 percent.

Yeah.

And if you hit 25 percent LV infarction you get cardiac dilation and clinical heart failure.

And if that infarction reaches 40 percent.

Cardiogenic shock and death are highly likely.

Geez.

So if irreversible cell death starts in just 20 minutes what can we do the second this patient hits the ER doors to buy them some time.

Well that brings us to our immediate routine drug therapies.

Because our goal is buying time and minimizing damage.

Right.

Clinical guidelines specifically the ACCF AHA SKI updates mandate interventions that minimize necrosis right away even while you are still confirming the exact diagnosis with an ECG.

OK so we usually start with an intervention that surprises a lot of people which is oxygen.

Yeah giving supplemental oxygen by nasal cannula to someone having a heart attack seems completely intuitive.

Right.

They lack oxygen so you provide it.

Right.

But according to current guidelines routine oxygen is actually not evidence based.

In fact there is data suggesting that excess oxygen might cause vasoconstriction and could actually increase mortality.

See that is a massive paradigm shift.

You don't just throw a non -rebreather on everyone who clutches their chest anymore.

No you don't.

Current guidelines recommend oxygen only if the patient's arterial saturation drops below 90 percent.

Got it.

Moving on to something everyone does get aspirin.

We know it suppresses platelet aggregation for an immediate antithrombotic effect.

But as a prescriber the administration instructions are crucial here.

You must instruct the patient to first dose of 162 to 325 milligrams.

Right because chewing allows for rapid absorption directly across the buccal mucosa getting the drug into the bloodstream much faster than swallowing it whole.

And then the patient continues a daily dose indefinitely.

Exactly.

There was a landmark trial back in the late 80s the ISIS 2 study that completely changed how we view aspirin.

Oh yeah.

It proved that aspirin alone caused a substantial reduction in mortality but the benefits were incredibly synergistic when combined with fibrinolytic or you know clot busting drugs.

Wait what were the numbers on that?

So with fibrinolytics alone mortality was 13 .2 percent but when they added aspirin mortality dropped to eight percent.

That's a huge drop.

But while aspirin is a foundational therapy the guidelines explicitly state that routine use of non -aspirin NSAIDs like ibuprofen or naproxen must be discontinued immediately.

Yeah they do the exact opposite of what we want.

They paradoxically increase the risk of mortality, reinfraction, heart failure and even that myocardial rupture we just talked about.

Scary stuff.

Now morphine is another staple right?

Serving a dual clinical role.

Yes.

Given intravenously it is the treatment of choice for STEMI -associated pain.

But it's not just an analgesic to make the patient comfortable.

Morphine actively improves hemodynamics.

It's treating the failing engine not just silencing the alarm bell.

Perfect analogy.

It promotes venodilation which pools blood in the periphery and reduces the amount of blood returning to the heart.

So that is a direct reduction in cardiac preload.

Exactly.

It also causes modest arterial dilation reducing afterload and by lowering both preload and afterload morphine significantly lowers the cardiac oxygen demand helping to preserve that ischemic tissue.

Let's talk about beta blockers.

To go back to our engine analogy giving cardio selective beta blockers is like forcing an overheating red lining engine into a lower gear to prevent it from blowing a gasket.

Yeah because as a STEMI evolves the sympathetic nervous system kicks into overdrive.

Traffic to the heart spikes and the number of beta receptors in the myocardium actually increases.

And this surge drives up the heart rate and contractility which violently increases the heart's demand for oxygen.

Right and we are desperately trying to reduce demand.

Exactly.

So beta blockers blunt that sympathetic activation by reducing heart rate and contractility they lower oxygen demand.

Furthermore by slowing the heart rate down they prolong the diastolic filling time.

And since the coronary arteries fill during diastole this means more time for blood to flow to the heart muscle actively increasing the myocardial oxygen supply.

Yes we're fixing the supply and demand imbalance from both ends but you have to know

Right you do not give beta blockers if the patient has severe heart failure pronounced breadycardia advanced heart block or cardiogenic shock.

Exactly.

Assuming those are absent oral dosing should begin within 24 hours.

Okay so our final routine drug is nitroglycerin.

It provides major hemodynamic benefits.

It does.

It reduces preload increases collateral blood flow to the ischemic region controls hypertension caused by the intense anxiety of having a heart attack and helps limit the overall infarct size.

But there is a massive caveat you need to highlight in your notes here.

Nitroglycerin does not reduce mortality.

Right it doesn't.

We use it because it's easily administered helps relieve ischemic chest pain and offers those hemodynamic benefits but it is not a lifesaver on its own.

And the dosing algorithm requires strict adherence.

For ongoing ischemic discomfort you give 0 .4 milligrams sublingually every five minutes for a maximum of three doses.

After that you assess for IV nitroglycerin.

And the contra indications are absolute.

Avoid it in hypotension specifically a systolic under 90 severe bready cardia under 50 beats per minute mark tachycardia over 100 or suspected right ventricular infarction.

And most importantly you must ask your patient about phosphodasterase inhibitors the drugs used for erectile dysfunction.

Yes this is critical.

If they've used sildenafil, fardenafil or evanafil the past 24 hours or tud -dedalifil in the past 48 hours nitroglycerin is completely contra indicated due to the risk of profound fatal hypotension.

So those routine drugs aspirin morphine beta blockers nitroglycerin they buy us precious time but they don't solve the underlying mechanical problem of the blocked artery.

No they don't.

Reprofusion therapy is the definitive intervention.

Restoring the flow is the single most effective way to preserve myocardial function and limit infarct size.

We essentially have two ways to open that block pipe.

Primary PCI or percutaneous coronary intervention and fibrinolytic therapy.

Let's look at PCI first.

Okay.

This is mechanical reperfusion balloon angioplasty coupled with placing a stent.

The institutional goal here is rapid implementation.

We want PCI performed within 90 minutes of initial patient contact.

Yeah and when you weigh the clinical data comparing PCI and fibrinolytics PCI emerges as clearly superior.

It really does.

The clinical decision boils down to a few distinct advantages.

PCI boasts higher initial reperfusion success rates leaves less residual stenosis in the artery and crucially doesn't carry the risk of promoting intracranial bleeding.

And the long -term data also supports taking them to the cath lab.

At 30 days the rate of death reinfraction or disabling stroke is 8 % with PCI versus 13 .7 % with fibrinolytic therapy and looking out almost eight years all cause mortality remains significantly lower with PCI.

But PCI requires an available catheterization lab and an experienced surgical team.

If you are in a facility that doesn't have universal access to that within the 90 -minute window you turn to chemical reperfusion which is fibrinolytic therapy.

These are your clot busting drugs like alteplase or tPA.

Mechanically they work by converting plasminogen into plasmin an enzyme that literally digests the fibrin mesh holding the clot together.

Exactly and the logistics for fibrinolytics are even tighter.

The target door to needle time is under 30 minutes.

Yeah and current guidelines strictly restrict their use to patients whose ischemic pain has been present for no more than 12 to 24 hours.

But since bleeding is the obvious glaring risk of literally dissolving clots in the vascular system how do we decide who actually gets these drugs safely?

Well you have to utilize a very clinical decision making framework.

First you look the ideal time window.

The GS2R trial which was a massive study looking at the timing and efficacy of these drugs showed that alteplase is most effective when given within four to six hours of symptom onset.

Especially in patients under 75 years old right?

And the terrifying major complication is bleeding specifically intracranial hemorrhage or ICH which happens in about 0 .5 percent to 1 percent of patients.

Yeah and because of that risk you must memorize the absolute contraindications.

You cannot administer fibrinolytics if there's any prior intracranial hemorrhage, known structural cerebrovascular lesions, active internal bleeding, or severe uncontrolled hypertension that is unresponsive to emergency therapy.

Okay so you've opened the vessel either mechanically with a stent or chemically with fibrinolytics but the body is stubborn.

Very.

The clotting cascade is agitated and it's immediately going to try and close that pipe right back up.

This means we have to deploy adjuncts to reperfusion therapy to maintain the flow.

Right anticoagulants are the first line of defense here but the timing depends entirely on your reperfusion strategy.

If you're using fibrinolytics you start IV heparin beforehand and continue it for 48 hours after to prevent rethrombosis.

Okay and if they are going to the cath lab for PCI?

For PCI a single dose of heparin is given right before the procedure.

You also have other anticoagulant options based on renal function and risk profiles.

Like low molecular weight heparin right like inoxaparin.

Yeah exactly but as a prescriber you must monitor the patient's creatinine clearance.

If their clearance is under 30 ml per minute you have to adjust that inoxaparin dose downward.

Makes sense.

Alternatively for PCI by valerudin which is a direct thrombin inhibitor is a preferred agent especially if you were combining it with certain antiplatelets.

Speaking of antiplatelet drugs beyond our initial aspirin we have the p2y12 inhibitors.

These drugs clopidogrel ticagrelor and proshagrel block the ADP receptors on platelets stopping them from aggregating.

If your patient gets a spent during PCI they will be taking one of these p2y12 inhibitors combined with aspirin for at least 12 months.

This is known as dual antiplatelet therapy.

Now if they received fibrinolytic therapy instead of PCI the guidelines currently recommend only clopidogrel as the p2y12 inhibitive choice taken for at least 14 days and up to a year.

Wait what about those super powerful IBE antiplatelets the glycoprotein IBEA inhibitors like terafibon and eptofibotide?

Ah yeah those target the final common pathway of platelet aggregation.

They are considered primarily for patients undergoing PCI who did not receive a p2y12 inhibitor beforehand or who have a massive thrombus burden.

Okay got it.

The final adjuncts we need to discuss tie perfectly back to the pathophysiology we started with.

Remember ventricular remodeling?

That dangerous reshaping of the heart driven by angiotensin the second.

This is where ACE inhibitors and ARBs come in to save the architecture of the heart.

Right ACE inhibitors like captoperol or lisinopril should be started within 24 hours of symptom onset.

By blocking the renin angiotensin aldosterone system they reduce both preload and afterload, prevent detrimental water retention, and favorably alter that ventricular remodeling.

Which significantly lowers mortality.

Definitely.

You do have to monitor for contraindications like hypotension and bilateral renal artery stenosis though.

But what if a patient gets that famous ACE inhibitor cough or just can't tolerate the drug?

Another major trial the Valiant study provided the answer there.

It proved that ARBs angiotensin receptor blockers like felsortin are a perfectly effective substitute.

Oh nice.

Yeah they provide the same mortality reduction in patients with heart failure or reduce LV function who cannot tolerate ACE inhibitors.

So we've created the acute event, we've opened the pipe and kept it open, but surviving the initial blockage is just the first hurdle.

We need to look at the immediate complications of a STEMI.

This is a critical point because the major cause of death post MI isn't actually the tissue necrosis itself.

It's the electrical chaos that the necrosis triggers.

Ventricular dysrhythmias are responsible for 60 percent of infarction related 60 percent.

That is a staggering number.

It really is.

The acute management for ventricular fibrillation is immediate defibrillation followed by an infusion of IV meadorone for 24 to 48 hours to stabilize the cardiac rhythm.

The second major complication is cardiogenic shock.

We touched on this earlier.

It is profound tissue hyperperfusion because the heart simply cannot pump enough blood to sustain the body.

It usually occurs in massive infarcts where the ejection fraction drops under 35 percent.

The mortality rate for cardiogenic shock in the hospital is up to 50 percent.

But there is a truly tragic clinical paradox here.

Yeah, walk us through it.

Well, when a patient is in cardiogenic shock, the standard instinct is to give inotropic agents like dopamine to force the heart to squeeze harder and increase cardiac output.

We give vasodilators to improve tissue perfusion.

And if you look at the monitors,

the hemodynamics actually improve.

The numbers look better.

But the text explicitly states that these drugs do not actually reduce mortality in cardiogenic shock.

Yeah, it's a harsh reality of advanced practice.

Yeah.

Whipping a dying horse,

I mean, forcing ischemic, dying myocardium to work harder,

doesn't save the tissue.

No.

The drugs support the failing system temporarily, but in cardiogenic shock, only actual restoration of cardiac perfusion can save the patient's life.

That means getting them to emergency PCI or coronary bypass grafting.

And the other complications you'll manage are heart failure and cardiac rupture.

Heart failure requires a coordinated polypharmacy approach, right?

Diuretics to decrease pulmonary congestion, degoxin to enhance contractility, and vasodilators and ACE inhibitors to reduce the load on the struggling heart.

Yeah.

And as for cardiac rupture, where the monocyte weakened myocardial wall literally tears open, it's relatively rare, carrying less than a 2 percent incidence.

Yeah.

The risk is highest in the first few days following a large anterior infarct.

The best way to mitigate this risk is early, aggressive treatment with beta blockers and vasodilators to reduce the sheer physical wall tension on that dying tissue.

All right.

Let's bring it home with secondary prevention and a summary of our key prescribing considerations.

So your uncomplicated STEMI patients survived the acute phase.

They can actually be discharged as early as 72 hours after admission.

True.

But the threat is far from over.

They face a 5 percent to 15 percent risk of experiencing a re -infarction within that very first year.

Wow.

So the long -term clinical strategy must pivot to aggressive risk reduction.

You have to set vital non -negotiable targets for them.

Strict total smoking cessation.

Blood pressure must be managed to under 130 over 80.

For diabetic patients and HbA1c, under 7 percent.

They need high -dose statin therapy, regardless of their baseline cholesterol, and they need to aim for 30 minutes of aerobic exercise three to four days a week.

And pharmacologically,

there are four classes of drugs that all post -MI patients must take indefinitely.

One, beta blockers.

Two, ACE inhibitors or ARBs.

Three, an antiplatelet or anticoagulant regimen.

And four, a statin.

All four of those pillars.

Indefinitely.

There is a specific safety warning from the text regarding hormone therapy, though.

Estrogen therapy for post -menopausal women is not effective for secondary prevention of an MI and absolutely must not be initiated for this purpose.

That's a great point to highlight.

And to summarize the overarching prescribing considerations from chapter 93,

your role in advanced practice is continuous clinical monitoring.

Always.

You are constantly watching the ECGs for ST segment changes, trending the cardiac troponins to measure infarct size, and checking bleeding markers and complete blood counts when utilizing these powerful

Because your ultimate therapeutic goal, the governing principle that drives every single decision from the field to the cath lab to discharge, is ensuring that oxygen supply outpaces demand safely.

Exactly.

Every drug, every dosage adjustment, every timing window serves that single goal.

Which leaves us with this final, provocative thought for you to reflect on as you integrate this material.

Think about the intense biological math of a STEMI.

Every single pharmacological choice we just discussed, from the seemingly simple mechanical act of chewing an aspirin, to the precise minute -by -minute timing of a fibrinolytic infusion is a desperate effort to manipulate an unforgiving 20 -minute cellular death clock.

It's a powerful reminder that in cardiology, time literally is tissue.

The faster and more accurately you act on these principles, the more of that engine you save.

Well, we want to conclude with a warm thank you from the last minute lecture team, wishing you luck in applying these frameworks in your advanced clinical practice.

Keep studying, and we'll see you next time.